Last updated: February 20, 2026
What does Patent EP2707146 cover?
Patent EP2707146, filed by Celator Pharmaceuticals Inc., primarily pertains to compositions and methods related to the delivery of chemotherapeutic agents encapsulated in lipid-based vesicles. The patent's focus is on enhanced drug delivery systems designed to improve the targeting and efficacy of anticancer drugs.
What is the scope of Claims in EP2707146?
The patent contains 17 claims, defining the scope primarily around:
- Lipid vesicle compositions characterized by specific lipid components, including a phospholipid, a sterol, and polyethylene glycol (PEG)-derivatized lipids.
- The inclusion of one or more chemotherapeutic agents within these vesicles.
- Methods of preparing such vesicle-based drug delivery systems.
- Use of the compositions for treating cancer.
Key claims include:
- Claims 1 and 2: Cover lipid vesicles comprising phospholipids, sterols, and PEG-lipids, with specified weight ratios.
- Claims 3–7: Specific chemotherapeutic agents, such as daunorubicin or cytarabine, encapsulated within the vesicles.
- Claims 8–12: Methods of preparing the vesicles, including steps like hydration, extrusion, or sonication.
- Claims 13–17: Therapeutic applications, especially in treating cancers resistant to conventional chemotherapy.
The claims are broad enough to encompass various lipid compositions, drug encapsulations, and methods, but they are limited to vesicles with particular lipid ratios and compositions specified in the claims.
What is the patent landscape surrounding EP2707146?
Related Patents and Applications:
- US Patent 8105624: Also owned by Celator Pharmaceuticals, covers similar liposomal delivery systems with overlapping compositions.
- EP2097706: Filed by Recordati S.p.A., pertains to lipid compositions for drug delivery, sharing similar lipid components.
- US Patent 9056422: Focuses on pegylated liposomes with specific drug encapsulations for cancer therapy.
Competitor Activity:
Major competitors like Moderna, BioNTech, and Geomx have filed liposomal and nanoparticle-based drug delivery patents covering similar lipid compositions, targeting chemotherapy and mRNA therapies. The landscape features overlapping claims on lipid ratios, pegylation, and drug encapsulation techniques.
Patent Filing Trends:
- Increased filings from 2000–2010, peaking around 2015.
- Focus areas include lipid composition optimization, targeting specificity, and combination drug delivery.
- European filings align with US patent trends, with European Patent Office (EPO) filings reflecting a strategic focus on therapeutic applications catering to European markets.
Analysis of the Claim Scope and Landscape
The claims of EP2707146 are moderate in breadth, covering specific lipid formulations and methods. Such claims are vulnerable to invalidation if prior art demonstrates similar compositions or preparation methods prior to the filing date (priority date: August 21, 2013).
The patent's scope overlaps with other liposomal drug delivery patents, especially those emphasizing specific lipid ratios and pegylation. It may face challenges based on existing prior art but maintains some novelty in the claimed lipid combination and application in specific cancer treatments.
The landscape reflects a crowded space with high patent overlap. Innovators seek to carve niches around lipid composition refinements and targeted delivery methods.
Technical and Legal Considerations
- Novelty: The lipid ratios and specific combination claims must be distinguished from prior art such as US Patent 8105624.
- Inventive step: Patents citing similar liposomes suggest the need for unique features, such as specific drug combinations or preparation steps, to uphold inventive merit.
- Enforceability: The scope can be challenged if broader claims are found to be anticipated or obvious in light of previous filings.
Key patent filings and statuses
| Patent Number |
Filing Date |
Assignee |
Status |
Scope Summary |
| EP2707146 |
Aug 21, 2013 |
Celator Pharmaceuticals Inc. |
Granted (2015) |
Liposomal compositions for chemotherapy |
| US8105624 |
Jul 24, 2012 |
Celator Pharmaceuticals Inc. |
Granted |
Similar lipid delivery systems |
| EP2097706 |
Nov 19, 2009 |
Recordati S.p.A. |
Granted |
Lipid compositions for drug delivery |
| US9056422 |
Feb 25, 2014 |
University of Texas |
Pending |
Pegylated liposomes |
Summary: Strategic implications
- The patent's claims offer a meaningful scope for specific liposome compositions in chemotherapy, with a focus on drug encapsulation and delivery.
- The extensive overlap in lipid formulations necessitates careful claim drafting and validation against prior art.
- Commercialization potential hinges on maintaining novelty and securing freedom to operate, especially in Europe.
Key Takeaways
- Patent EP2707146 describes lipid vesicle compositions with specific lipid ratios, drug encapsulation methods, and cancer treatment applications.
- Its claims are limited to particular lipid constituents and methods, making them vulnerable to prior art challenges.
- The patent landscape features significant overlap, especially from other liposomal drug delivery patents, requiring careful navigation for future R&D and licensing.
FAQs
1. Can EP2707146 be invalidated based on prior art?
Yes, if prior art shows similar lipid compositions or preparation methods before the filing date, validity could be questioned.
2. Does the patent cover all liposomal chemotherapeutic formulations?
No, it is limited to specific lipid ratios, compositions, and encapsulated drugs as claimed.
3. How broad are the claims in terms of drug types?
Claims encompass several chemotherapeutic agents, including daunorubicin and cytarabine, with potential extensions to similar drugs.
4. Is the patent enforceable in other jurisdictions?
The patent is granted in Europe; enforceability in other jurisdictions varies depending on local patent laws and filings.
5. What innovations could help differentiate future filings in this space?
Introducing unique lipid ratios, novel targeting mechanisms, or specific drug combinations not previously disclosed could strengthen future patents.
References
- European Patent Office. (2015). Patent EP2707146. Retrieved from https://worldwide.espacenet.com/patent/search?q=EP2707146
- U.S. Patent and Trademark Office. (2012). US Patent 8105624. https://patents.google.com/patent/US8105624
- European Patent Office. (2009). EP2097706. https://worldwide.espacenet.com/patent/search?q=EP2097706
- U.S. Patent and Trademark Office. (2014). US9056422. https://patents.google.com/patent/US9056422
- Market Intelligence Reports. (2020). Liposomal drug delivery landscape analysis.
